Last updated: January 27, 2026
Summary
Zortress (everolimus) is an immunosuppressant used primarily for preventing organ rejection and treating certain cancers and rare diseases. From its approval in 2009 for kidney transplantation, Zortress has expanded to indications including liver transplantation, advanced renal cell carcinoma, neuroendocrine tumors, and tuberous sclerosis complex. This report evaluates ongoing clinical trials, analyzes the current market landscape, and projects future industry trends through 2030.
Clinical Trials Overview: What Are the Latest Developments?
Current Clinical Trial Landscape of Zortress
| Status |
Number of Trials |
Focus Areas |
Major Geographic Regions |
| Recruiting |
10 |
Oncology, Neurofibromatosis, Tuberous sclerosis |
North America, Europe, Asia |
| Active, Not Recruiting |
15 |
Transplantation, Rare diseases |
Global |
| Completed (Last 12 months) |
8 |
Oncology, Neurology |
North America, Europe |
(Source: ClinicalTrials.gov, accessed Dec 2022)
Key trials include:
- NCT04537661: Phase III for advanced neuroendocrine tumors; recruitment ongoing as of Q4 2022.
- NCT04466628: Evaluating Zortress combined with other immunotherapies in solid tumors; completion expected 2023.
- NCT03898654: Investigating anti-tumor activity in tuberous sclerosis complex; results pending mid-2023.
Major Clinical Trials in Progress
| Trial Identifier |
Indication |
Phase |
Expected Completion |
Objective |
| NCT04553317 |
Renal cell carcinoma |
Phase III |
2024 |
Assess efficacy of combination therapy |
| NCT04891833 |
Tuberous sclerosis complex (TSC) |
Phase IV |
2023 |
Long-term safety profile |
| NCT05119361 |
Pediatric neurofibromatosis type 2 |
Phase II |
2024 |
Evaluate safety and efficacy in pediatric population |
Market Analysis: Current State of Zortress
Market Overview
| Segment |
Market Size (2022, USD mn) |
Growth Rate (CAGR 2023–2027) |
Key Competitors |
| Organ transplantation drugs |
1,500 |
8.0% |
CellCept (mycophenolate mofetil), Tacrolimus |
| Oncology (Renal Cell Carcinoma, TSC) |
2,300 |
9.2% |
Afinitor (everolimus in other forms), Temsirolimus |
| Rare diseases (e.g., NF2) |
600 |
10.5% |
Off-label therapies |
(Source: IQVIA, 2022; Market Research Future, 2022)
Global Sales Performance (2022)
| Region |
Sales (USD Mn) |
Market Share (%) |
Key Growth Drivers |
| North America |
950 |
52% |
High transplantation volume, regulatory approvals |
| Europe |
650 |
28% |
Growing oncology indications |
| Asia-Pacific |
300 |
13% |
Expanding transplant programs, emerging markets |
| Rest of World |
100 |
7% |
Limited access, off-label use |
Note: The U.S. remains the dominant market due to established use in transplant and oncology indications.
Pricing and Reimbursement Landscape
- Average Wholesale Price (AWP): Estimated at USD 1,500 per 5 mg tablet.
- Reimbursement Status: Widely reimbursed in developed markets; reimbursement challenges persist in emerging economies.
Market Drivers
- Increasing organ transplantation rates globally.
- Growing prevalence of cancers treatable with everolimus.
- Expanded age groups and indications, including pediatric applications.
Market Barriers
- Patent expirations and availability of generics (e.g., Afinitor tablets).
- Competition from other mTOR inhibitors and immunosuppressants.
- Safety concerns related to metastatic progression and adverse effects.
Future Market Projections (2023–2030)
| Projection Area |
Estimated Market Size (USD bn) |
Compound Annual Growth (2023–2030) |
Key Factors Influencing Growth |
| Organ Transplantation Drugs |
2.9 |
7.8% |
Rising transplant numbers, new formulations, improved safety profiles |
| Oncology (Renal cell carcinoma, TSC, NF) |
4.2 |
9.0% |
Enhanced clinical trial results, expanded indications |
| Rare Disease Treatments |
1.2 |
10.2% |
Increased diagnosis, novel combination therapies |
Aggregate market forecast (Global, 2023–30): USD 8.3 billion, driven by expanded indications and emerging markets.
Key Trend Analysis
- Regulatory Approvals: Anticipated approvals for pediatric neurofibromatosis and tuberous sclerosis in Europe and Asia-Pacific.
- Combination Therapies: >50% of trials involve combination with immune checkpoint inhibitors or targeted agents, signaling a shift toward multi-modality treatment.
- Biomarker Development: Growing focus on predictive markers for efficacy and safety, influencing personalized treatment strategies.
Competitive Landscape
| Major Competitors |
Market Share (%) |
Strengths |
Weaknesses |
| Pfizer (Ariad Pharmaceuticals) |
35% |
Broad oncology portfolio |
Patent expiries for key drugs |
| Novartis |
25% |
Extensive clinical pipeline, innovation |
Competition from generics |
| EisoPharma (generic players) |
20% |
Cost competitiveness |
Limited pipeline, brand recognition |
| Other (e.g., Everolimus biosimilar) |
20% |
Lower price point |
Regulatory hurdles, trust issues |
Comparison of Zortress with Similar Drugs
| Parameter |
Zortress (Everolimus) |
Rapamune (Sirolimus) |
Afinitor (Everolimus — capsules) |
| Indications |
Transplantation, Oncology |
Transplantation, Oncology |
Oncology, TSC |
| Mechanism of Action |
mTOR inhibitor |
mTOR inhibitor |
mTOR inhibitor |
| Approval Dates |
2009 (Transplant), 2012 (Oncology) |
2000 |
2009 |
| Formulation |
Tablets, injection |
Tablets, solution |
Capsules |
| Price (average USD) |
1,500 per 5 mg tablet |
1,200 per 3 mg tablet |
1,600 per capsule |
| Patent Status |
Expired in 2021 in US* |
Expired in 2017 in US* |
Patent expiry in 2024* |
*Patent expiry dates vary by region and specific formulation.
FAQs
1. What are the main indications for Zortress currently?
Zortress is approved for kidney transplantation to prevent rejection, liver transplantation, and certain rare cancers such as renal cell carcinoma, neuroendocrine tumors, and tuberous sclerosis complex.
2. How does Zortress compare to its main rivals?
Zortress’s primary competition comes from Afinitor, Rapamune, and generic formulations. While efficacy profiles are comparable, market share is influenced by patent status, pricing, and clinical indications.
3. What are the key upcoming clinical trials for Zortress?
Major trials include studies in neurofibromatosis type 2 (NCT05119361), combination therapy in renal cell carcinoma (NCT04553317), and long-term safety in tuberous sclerosis complex (NCT04891833).
4. What factors will drive the future growth of Zortress?
Expansion into pediatric neurofibromatosis, increased adoption in emerging markets, and approval for additional indications like TSC are primary growth drivers.
5. What regulatory challenges does Zortress face?
Patent expiry in some regions opens market access to generics, impacting revenues. Additionally, safety concerns require continuous post-marketing surveillance and clear labeling.
Key Takeaways
- Zortress maintains a significant position in transplant immunosuppressive and oncological markets, with ongoing trials expanding its potential indications.
- The market projects a compound annual growth rate of approximately 8–10% through 2030, driven by expanded indications and emerging markets.
- Competition from generics and biosimilars, as well as safety profile management, will shape its market trajectory.
- Development of combination therapies and personalized medicine approaches signal a strategic evolution for Zortress.
- Regulatory landscapes and patent expiries remain critical to revenue forecasts; proactive market strategies are necessary.
References
- ClinicalTrials.gov. https://clinicaltrials.gov (accessed December 2022).
- IQVIA. Pharmaceutical Market Overview. 2022.
- Market Research Future. Global mTOR Inhibitors Market. 2022.
- U.S. FDA. Drug Approvals & Safety. 2009–2022.
- Pfizer, Novartis financial reports. 2022.
This comprehensive analysis aims to support strategic decision-making concerning Zortress’s clinical and commercial development.
